Delwart E L, Pan H, Neumann A, Markowitz M
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA.
J Virol. 1998 Mar;72(3):2416-21. doi: 10.1128/JVI.72.3.2416-2421.1998.
Plasma human immunodeficiency virus type 1 (HIV-1) populations were genetically analyzed at their most variable locus, the envelope gene, during the rapid emergence of resistance to protease inhibitor monotherapy. Plasma virus populations remained genetically constant prior to drug treatment and during the 1 to 2 weeks following initiation of therapy, while viremia fell 10- to 100-fold. Concomitant with rapid plasma viremia rebounds associated with the emergence of drug-resistant virus, marked alterations were then detected at the env locus. Plasma population changes lasted only a few weeks before the reappearance of the pretreatment envelope variants. The emergence of resistance to single protease inhibitors was therefore associated with major but transient changes at a nonselected locus. Selection for resistance to single protease inhibitors thus appears to be more complex than the continued replication of a large, random, and therefore genetically representative sampling of the pretreatment plasma population. The possibility that drug-privileged anatomical sites containing distinct envelope variants and/or a small effective HIV-1 population size account for these results is discussed.
在对蛋白酶抑制剂单一疗法产生耐药性的快速出现过程中,对血浆中1型人类免疫缺陷病毒(HIV-1)群体在其最易变的位点即包膜基因进行了基因分析。在药物治疗前以及治疗开始后的1至2周内,血浆病毒群体在基因上保持恒定,而病毒血症下降了10至100倍。伴随着与耐药病毒出现相关的血浆病毒血症快速反弹,随后在env位点检测到明显变化。血浆群体变化仅持续了几周,然后预处理包膜变体再次出现。因此,对单一蛋白酶抑制剂产生耐药性与未选择位点的重大但短暂变化有关。对单一蛋白酶抑制剂耐药性的选择似乎比预处理血浆群体中大量、随机且因此具有基因代表性的样本的持续复制更为复杂。讨论了含有不同包膜变体的药物特权解剖部位和/或小的有效HIV-1群体规模导致这些结果的可能性。